Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Selectieve TrkA-remmer VMD-928 voor de behandeling van door TrkA-overexpressie aangedreven solide tumoren of lymfoom

30 oktober 2026 bijgewerkt door: VM Oncology, LLC

Een open-label onderzoek met meerdere doses en dosisescalatie om de veiligheid, farmacokinetiek en farmacodynamiek van VMD-928 te onderzoeken bij proefpersonen met solide tumoren of lymfoom

This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to available therapies and for which no standard or available curative therapy exists

Studie Overzicht

Gedetailleerde beschrijving

This is an open-label, dose-escalation (Phase 1) and expansion (Phase 2) multi-center study conducted in five parts to identify the safe and pharmacologically active doses (MTD and/orRP2D) and regimen for oral VMD-928 monotherapy and in combination with a PD-1 inhibitor, pembrolizumab in cancer patients. An immunohistochemistry (IHC) assay specific for detecting TrkA protein in tumor tissue samples has been validated and is being used to detect TrkA protein expressions in patient tumor tissue samples at Pre-screening. The study is currently focusing on the top 5 solid tumor with the highest TrkA protein overexpression are: Head and Neck Cancers (HNC), Esophageal cancer, Lung cancers, Mesothelioma, and Pancreatic Cancer.

Studietype

Ingrijpend

Inschrijving (Geschat)

242

Fase

  • Fase 2
  • Fase 1

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

      • San Juan, Puerto Rico, 00935
    • California
      • Santa Rosa, California, Verenigde Staten, 95403
    • Connecticut
      • Hartford, Connecticut, Verenigde Staten, 06102
    • District of Columbia
      • Washington D.C., District of Columbia, Verenigde Staten, 20037
        • Werving
        • The George Washington University Cancer Center (site 212)
        • Contact:
        • Hoofdonderzoeker:
          • Pavani Chalasani, MD, MPH
        • Contact:
    • Florida
      • Fort Lauderdale, Florida, Verenigde Staten, 33308
      • Pembroke Pines, Florida, Verenigde Staten, 33028
        • Werving
        • Memorial Cancer Institute at Memorial Healthcare Systems (site 132)
        • Hoofdonderzoeker:
          • Luis E Raez, MD
        • Contact:
        • Contact:
    • New Jersey
      • Englewood, New Jersey, Verenigde Staten, 07631
      • Florham Park, New Jersey, Verenigde Staten, 07932
        • Werving
        • Summit Medical Group (site 205)
        • Contact:
        • Hoofdonderzoeker:
          • Steven Papish, MD, FACP
      • Morristown, New Jersey, Verenigde Staten, 07962
    • New Mexico
      • Albuquerque, New Mexico, Verenigde Staten, 87110
        • Werving
        • Presbyterian Kaseman Hospital (site 208)
        • Contact:
        • Hoofdonderzoeker:
          • Ethan Binder, MD
        • Contact:
    • New York
      • New York, New York, Verenigde Staten, 10065
        • Werving
        • Weill Cornell Medicine, Cornell University (site 126)
        • Contact:
        • Contact:
        • Hoofdonderzoeker:
          • Ashish Saxena, M.D., Ph.D.
    • Pennsylvania
      • York, Pennsylvania, Verenigde Staten, 17403
        • Werving
        • Cancer Care Associates of York (site 206)
        • Hoofdonderzoeker:
          • Chanh Huynh, MD
        • Contact:
        • Contact:
    • Texas
      • Houston, Texas, Verenigde Staten, 77030
        • Werving
        • The University of Texas MD Anderson Cancer Center (site 127)
        • Hoofdonderzoeker:
          • David S Hong, MD
        • Contact:
        • Contact:

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 80 jaar (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Key Inclusion Criteria:

#. Histologically or cytologically confirmed diagnosis of any type of solid tumor malignancy or lymphoma:

Phase 1 Dose Escalation only: Subjects with

(A) any advanced solid tumors of

  1. Head and Neck Cancers ("HNC") (of any types),
  2. Esophageal cancer,
  3. Lung cancers (of any types),
  4. Mesothelioma,
  5. Pancreatic cancers,

Or,

(B) any NTRK1 gene fusion positive ("NTRK1+") solid tumors or lymphomas, that is relapsed, refractory or intolerant (R/R/I) to standard of care (SOC) and for which there is no approved or curative therapy. Additionally, patients must not be candidates for or have exhausted regimens known to provide clinical benefit, including hematopoietic stem cell transplantation in lymphoma patients if they are deemed transplant eligible.

Phase 2 Monotherapy and Combination with Pembrolizumab only:

Subjects must have

  1. TrkA-driven HNC, Esophageal, Lung, Mesothelioma, Pancreatic cancers; or,
  2. any NTRK1+ solid tumors or lymphoma*, that is R/R/I to SOC.

Key Inclusion Criteria:

  • Eastern Cooperative Oncology Group (ECOG) Performance Status: 0 or 1.

  • Able to swallow and retain oral medication.

  • Subjects must either have available archival tumor tissue samples, or consent to tumor tissue sampling prior to the first dose.

  • Adequate organ system function as defined as follows:

    1. Absolute neutrophil count ≥1.5x10^9/L
    2. Hemoglobin ≥9g/dL
    3. Platelets ≥100x10^9/L
    4. PT/INR, PTT ≤1.5xULN
    5. Total bilirubin ≤1.5x ULN
    6. AST, ALT ≤2.5xULN
    7. Creatinine ≤1.2xULN for age, weight
    8. Calculated creatinine clearance or 24h urine creatinine clearance ≥60mL/min

Key Exclusion Criteria:

  • Received chemotherapy having delayed toxicity within the last 14 days (six weeks for prior nitrosourea or mitomycin C).

  • Received anticancer therapy with radiation, immunotherapy, and a biologic, surgery and/or tumor embolization within the past 2 weeks.

  • Received an investigational anticancer drug within 14 days or 5 half-lives of the investigational agent, whichever is longer, prior to the first dose of VMD-928. Any exceptions to the above must be approved by the Sponsor Medical Monitor.

  • Unresolved toxicity from previous anticancer therapy > CTCAE Grade 1 (except alopecia or anemia) unless agreed to by both the Sponsor Medical Monitor and the Investigator.

  • Known active infections including HIV disease.

  • Currently pregnant, nursing, or planning to become pregnant during the course of the study.

  • QTcF interval ≥ 480 msec.

  • Class II, III, or IV heart failure as defined by the New York Heart Association (NYHA) functional classification system.

  • Acute coronary syndromes (including unstable angina), coronary angioplasty, or stenting within the past 24 weeks.

  • Unstable or uncompensated respiratory, hepatic, renal, or cardiac disease that would compromise the patient's safety or interfere with assessment of the drug.

  • Psychological, familial, sociological, geographical, or other concurrent conditions that would interfere with safety evaluation, limit the patient's ability to follow the procedures in the protocol or otherwise jeopardize compliance with the protocol. Patients with uncontrolled major depression, bipolar disorder, or severe anxiety disorder are excluded.

  • Patient has had or is currently having other malignant tumors within 3 years.

  • Patients have multiple factors that affect their oral medication.

  • Patients have long-term unhealed wounds or fractures.

  • Patients have uncontrolled pleural effusion, pericardial effusion, or ascites that still require repeated drainage.

  • Patients are taking the following drugs and can't stop them during the study:

    • Tylenol or medicine containing acetaminophen (paracetamol).
    • Antacids (e.g. TUMS, calcium carbonate, or magnesium hydroxide), proton pump inhibitors (e.g. omeprazole), H2 blockers (e.g. famotidine), or buffered vitamins.
  • Epstein-Barr virus (EBV) negative nasopharyngeal carcinoma.

For Phase 2 only:

  • Negative result on TrkA immunohistochemistry (IHC) assay.
  • Have visceral crisis, defined as severe organ dysfunction and rapid progression of the cancer. (It is not about presence of visceral metastasis.)

For combination therapy with Pembrolizumab only:

  • Serious adverse immune related adverse events (grade 3 or 4) with previous PD-1(L1) inhibitor therapy, that were symptomatic and required prolong immunosuppression (>6 weeks).
  • Any grade Pneumonitis and Myocarditis related to prior PD-1(L1) inhibitor therapy.
  • For subjects that received PD-1(L1) inhibitors before, there should be a washout period of at least 21 days between the last day of PD-1(L1) inhibitor and first day of study medications.
  • Subjects who relapsed after prior treatment with PD-1(L1) inhibitors. Relapsed is defined as patients having best overall response of CR or PR after treatment with a PD-1(L1) inhibitor.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Niet-gerandomiseerd
  • Interventioneel model: Sequentiële toewijzing
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: VMD-928 monotherapy

VMD-928 tablet monotherapy

Taken orally once daily for 21 days per 21-day cycle

Andere namen:
  • Monotherapie
Experimenteel: Combination Therapy

VMD-928 tablet in combination with fixed dose of pembrolizumab 200 mg once-very-21-day (per cycle)

VMD-928 tablet (oral) starting at 300 mg daily for 21 days of 21-day cycle. Pemprolizumab at fixed intravenous dose of 200 mg once-every-21 days (per cycle) for max. 6 cycles.

Andere namen:
  • Combinatietherapie

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Number and severity of treatment-emergent Adverse Events (Phase 1)
Tijdsspanne: First cycle (21 days per cycle)

TEAE

First cycle (21 days per cycle)
To determine the recommended Phase 2 dose for VMD-928 (Phase 1)
Tijdsspanne: First cycle (21 days per cycle)

RP2D of monotherapy

First cycle (21 days per cycle)
To determine the RP2D of VMD-928 in combination with pembrolizumab (Phase 1)
Tijdsspanne: First cycle (21 days per cycle)

RP2D of combination therapy

First cycle (21 days per cycle)
Antitumor activity of VMD-928 in subjects with TrkA-driven tumors (Phase 2)
Tijdsspanne: Up to 18 months

Antitumor efficacy signal for monotherapy

Up to 18 months
Antitumor activity of VMD-928 in combination with pembrolizumab in subjects with TrkA-driven tumors (Phase 2)
Tijdsspanne: Up to 18 months

Antitumor efficacy signal for combination therapy

Up to 18 months

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Area under the plasma concentration versus time curve (AUC) of VMD-928.
Tijdsspanne: On Day 1 and Day 15 of Cycle 1 (each cycle is 21 days)

AUC

On Day 1 and Day 15 of Cycle 1 (each cycle is 21 days)
Peak plasma concentration (Cmax) of VMD-928.
Tijdsspanne: On Day 1 and Day 15 of Cycle 1 (each cycle is 21 days)

Cmax

On Day 1 and Day 15 of Cycle 1 (each cycle is 21 days)
Incidence of Dose Limiting Toxicities.
Tijdsspanne: During the Cycle 1 (each cycle is 21 days)

# of DLTs

During the Cycle 1 (each cycle is 21 days)
Correlation between clinical antitumor and TrkA protein expression.
Tijdsspanne: Up to the end of the Cycle 2 (each cycle is 21 days)

Relationship of TrkA vs. efficacy

Up to the end of the Cycle 2 (each cycle is 21 days)

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Studie stoel: Clinical Development, VM Oncology

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

8 juni 2018

Primaire voltooiing (Geschat)

1 december 2027

Studie voltooiing (Geschat)

1 juni 2028

Studieregistratiedata

Eerst ingediend

29 april 2018

Eerst ingediend dat voldeed aan de QC-criteria

1 juni 2018

Eerst geplaatst (Werkelijk)

14 juni 2018

Updates van studierecords

Laatste update geplaatst (Werkelijk)

4 november 2026

Laatste update ingediend die voldeed aan QC-criteria

30 oktober 2026

Laatst geverifieerd

1 oktober 2026

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • VMO-01C

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

ONBESLIST

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren